Advertisement


Howard S. Hochster, MD, on Colorectal Cancer: Results From the E7208 Trial

2018 ASCO Annual Meeting

Advertisement

Howard S. Hochster, MD, of Rutgers-Cancer Institute of New Jersey, discusses study findings on irinotecan and cetuximab vs irinotecan, cetuximab, and ramucirumab as second-line therapy of advanced colorectal cancer following oxaliplatin and bevacizumab-based therapy (Abstract 3504).



Related Videos

Prostate Cancer

Sumanta K. Pal, MD, and Neeraj Agarwal, MD, on Prostate Cancer: The Talapro-2 Trial

Sumanta K. Pal, MD, of the City of Hope, and Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discuss the ongoing phase III Talapro-2 study of talazoparib with background enzalutamide in metastatic castration-resistant prostate cancer with DNA damage–repair deficiencies (Abstract TPS5091).

Leukemia

William G. Wierda, MD, PhD, and Julie M. Vose, MD, MBA, on CLL: Results From the CAPTIVATE Trial

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discuss phase II findings on ibrutinib plus venetoclax in first-line treatment of chronic lymphocytic leukemia (Abstract 7502).

Breast Cancer

Andrew D. Seidman, MD, and Susan F. Dent, MD, on Breast Cancer: Analysis of the SANDPIPER Trial

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Susan F. Dent, MD, of The Ottawa Hospital Cancer Centre, analyze the phase III study findings on taselisib plus fulvestrant vs fulvestrant in patients with estrogen receptor–positive, PIK3CA-mutant, locally advanced or metastatic breast cancer (Abstract LBA1006).

Kidney Cancer
Immunotherapy

Bernard J. Escudier, MD, on RCC: Results From the IMmotion151 Trial

Bernard J. Escudier, MD, of Gustave Roussy, discusses patient-reported outcomes for atezolizumab plus bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma (Abstract 4511).

Breast Cancer
Immunotherapy

Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Results From the GeparNuevo Trial

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses phase II study findings on the addition of durvalumab to a taxane-anthracycline–containing chemotherapy in triple-negative breast cancer (Abstract 104).

Advertisement

Advertisement




Advertisement